[
  {
    "ts": null,
    "headline": "Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’",
    "summary": "We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since […]",
    "url": "https://finnhub.io/api/news?id=9900409e13a002e64bff25e45dad06e544c5951c20ebb033e125fc366128a3e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746128414,
      "headline": "Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’",
      "id": 134185148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since […]",
      "url": "https://finnhub.io/api/news?id=9900409e13a002e64bff25e45dad06e544c5951c20ebb033e125fc366128a3e6"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a week where the broader market witnessed a 2.7% rise, Regeneron’s stock nudged up 1.86%. Although the company’s announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market’s overall positive momentum, partly...",
    "url": "https://finnhub.io/api/news?id=b2a308818b59e7e87094a7086499f3e2d6aee60a173a55d233847f1a2c8ca46e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746121270,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences",
      "id": 134185149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a week where the broader market witnessed a 2.7% rise, Regeneron’s stock nudged up 1.86%. Although the company’s announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market’s overall positive momentum, partly...",
      "url": "https://finnhub.io/api/news?id=b2a308818b59e7e87094a7086499f3e2d6aee60a173a55d233847f1a2c8ca46e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=ccc40a4a5d53455792917621237867884b2539d5bce80eef480648b98266c9a0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746117840,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 134194051,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=ccc40a4a5d53455792917621237867884b2539d5bce80eef480648b98266c9a0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals : Q1 2025 Earnings Conference Call Transcript",
    "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT REGN.OQ - Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call EVENT DATE/TIME: APRIL 29, 2025 / 12:30PM GMT ...",
    "url": "https://finnhub.io/api/news?id=10b31c8eaf675cefe8eee57f6b86d1fafbe08304678803cfdf8e73f742e0f387",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746116489,
      "headline": "Regeneron Pharmaceuticals : Q1 2025 Earnings Conference Call Transcript",
      "id": 134177084,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "REFINITIV STREETEVENTS EDITED TRANSCRIPT REGN.OQ - Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call EVENT DATE/TIME: APRIL 29, 2025 / 12:30PM GMT ...",
      "url": "https://finnhub.io/api/news?id=10b31c8eaf675cefe8eee57f6b86d1fafbe08304678803cfdf8e73f742e0f387"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron price target lowered to $940 from $975 at Truist",
    "summary": "Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving bre",
    "url": "https://finnhub.io/api/news?id=ef6e0ced5042822bbd993edbaab9e6ef19306f6270f6283134877890961186a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746109252,
      "headline": "Regeneron price target lowered to $940 from $975 at Truist",
      "id": 134173806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving bre",
      "url": "https://finnhub.io/api/news?id=ef6e0ced5042822bbd993edbaab9e6ef19306f6270f6283134877890961186a8"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination",
    "summary": "18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodiesTARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights",
    "url": "https://finnhub.io/api/news?id=623c3ee4823fe493f8f452ab5543b8b11fec87748e999ade75eabd4e7832ea93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746106200,
      "headline": "Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination",
      "id": 134173807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodiesTARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights",
      "url": "https://finnhub.io/api/news?id=623c3ee4823fe493f8f452ab5543b8b11fec87748e999ade75eabd4e7832ea93"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases",
    "summary": "24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase",
    "url": "https://finnhub.io/api/news?id=d298687f208e18edc658e330b5f9b8007f4f52325bfc828239d6ad64a221db57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746104400,
      "headline": "Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases",
      "id": 134173808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase",
      "url": "https://finnhub.io/api/news?id=d298687f208e18edc658e330b5f9b8007f4f52325bfc828239d6ad64a221db57"
    }
  }
]